Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN).
J Neuroimmune Pharmacol. 2013; 8: 470-476
Naltrexone: not just for opioids anymore.
J Med Toxicol. 2016; 12: 71-75
Naltrexone pharmacology, pharmacokinetics, and metabolism: current status.
Am J Drug Alcohol Abuse. 1975; 2: 357-363
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Clin Rheumatol. 2014; 33: 451-459
Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function.
Altern Ther Health Med. 2013; 19: 56-65
The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders.
Pharmacotherapy. 2018; 38: 382-389
Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain.
J Anesth. 2019; 33: 131-139
Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury.
Glia. 2010; 58: 253-263
Targeting toll-like receptor-4 (TLR4)-an emerging therapeutic target for persistent pain states.
Pain. 2018; 159: 1908-1915
Glia in mammalian development and disease.
Development. 2015; 142: 3805-3809
Central Pain Syndrome.
StatPearls,
Treasure Island, FL2020
Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness.
Semin Arthritis Rheum. 2008; 37: 339-352
Glia and pain: is chronic pain a gliopathy? Pain. 2013; 154: S10-S28
Activation of P2X7 receptors in glial satellite cells reduces pain through downregulation of P2X3 receptors in nociceptive neurons.
Proc Natl Acad Sci U S A. 2008; 105: 16773-16778
Role of astrocytes in pain.
Neurochem Res. 2012; 37: 2419-2431
Astroglial glutamate-glutamine shuttle is involved in central sensitization of nociceptive neurons in rat medullary dorsal horn.
J Neurosci. 2007; 27: 9068-9076
BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain.
Nature. 2005; 438: 1017-1021
Satellite glial cells in sensory ganglia: their possible contribution to inflammatory pain.
Brain Behav Immun. 2007; 21: 592-598
Targeting astrocyte signaling for chronic pain.
Neurotherapeutics. 2010; 7: 482-493
Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain.
J Neurosci. 2007; 27: 6006-60018
Glial cell plasticity in sensory ganglia induced by nerve damage.
Neuroscience. 2002; 114: 279-283
Can satellite glial cells be therapeutic targets for pain control?.
Neuron Glia Biol. 2010; 6: 63-71
Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway.
Neuron Glia Biol. 2006; 2: 259-269
p38 MAPK, microglial signaling, and neuropathic pain.
Mol Pain. 2007; 3: 33
Activation of satellite glial cells in lumbar dorsal root ganglia contributes to neuropathic pain after spinal nerve ligation.
Brain Res. 2012; 1427: 65-77
The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat.
Neuropharmacology. 1994; 33: 1471-1478
Astroglia in medullary dorsal horn (trigeminal spinal subnucleus caudalis) are involved in trigeminal neuropathic pain mechanisms.
J Neurosci. 2009; 29: 11161-11171
Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy.
J Pharmacol Exp Ther. 2003; 306: 624-630
Interactions between the immune and nervous systems in pain.
Nat Med. 2010; 16: 1267-1276
Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing.
J Neurochem. 2003; 86: 1534-1544
P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury.
Nature. 2003; 424: 778-783
Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat.
Pain. 1997; 71: 225-235
Altered functional properties of satellite glial cells in compressed spinal ganglia.
Glia. 2009; 57: 1588-1599
HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia.
Gene Ther. 2008; 15: 183-190
The prevalence of chronic pain in United States adults: results of an Internet-based survey.
J Pain. 2010; 11: 1230-1239
Estimates of pain prevalence and severity in adults: United States, 2012.
J Pain. 2015; 16: 769-780
Population-based survey of pain in the United States: differences among white, African American, and Hispanic subjects.
J Pain. 2004; 5: 317-328
Persistent pain and well-being: a World Health Organization study in primary care.
JAMA. 1998; 280: 147-151
The impact of chronic pain in the community.
Fam Pract. 2001; 18: 292-299
Opioids and the treatment of chronic pain: controversies, current status, and future directions.
Exp Clin Psychopharmacol. 2008; 16: 405-416
Epidemiology of chronic pain with psychological comorbidity: prevalence, risk, course, and prognosis.
Can J Psychiatry. 2008; 53: 224-234
Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02.
Vital Health Stat 13. 2006; : 1-66
Opioid abuse in chronic pain: misconceptions and mitigation strategies.
N Engl J Med. 2016; 374: 1253-1263
Fibromyalgia: a clinical review.
JAMA. 2014; 311: 1547-1555
Pain mechanisms and centralized pain in temporomandibular disorders.
J Dent Res. 2016; 95: 1102-1108
Chinese medicine users in the United States, part II: preferred aspects of care.
J Altern Complement Med. 1998; 4: 189-202
Assessment of patients’ perceptions and beliefs regarding herbal therapies.
Pharmacotherapy. 2000; 20: 83-87
Use of alternative medicine by patients undergoing cardiac surgery.
J Thorac Cardiovasc Surg. 2000; 120: 335-341
Use of complementary and alternative medicine for temporomandibular disorders.
J Orofac Pain. 2003; 17: 224-236
Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
Arthritis Rheum. 2013; 65: 529-538
Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.
Pain Med. 2009; 10: 663-672
Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone.
Discov Med. 2018; 26: 197-206
Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia.
Biomedicines. 2017; 5: 16
Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?.
Psychosomatics. 2012; 53: 591-594
Proceedings #47: low dose naltrexone: a viable alternative for long term chronic pain?.
Brain Stimul. 2019; 12: e118-e120
Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients.
Int J Pharm Compound. 2016; 20: 197-201
